MCUJF — MEDICURE INC

OTC · Health Care · Pharmaceuticals · CIK 1133519 · Manitoba, Canada
Last close
$0.80
Market Cap
$8.35M
52W High
$0.96
52W Low
$0.75
ADV30
207
Next earnings
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order, and online pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Dec 2025 8,543,000 2,697,000 -4,224,000 -4,221,000 24,949,000 3,835,000 12,040,000
Sep 2025 8,159,000 2,773,000 -1,310,000 -1,396,000 26,723,000 4,118,000 9,415,000
Jun 2025 6,669,000 3,435,000 -699,000 -786,000 28,412,000 4,739,000 10,105,000
Mar 2025 5,484,000 2,843,000 -655,000 -694,000 29,778,000 7,216,000 9,683,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-560,000
Investing CF
$-2,042,000
Financing CF
$-415,000
CapEx
$-548,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.21
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-73,988,000
Inventory
$2,942,000
Receivables
$4,817,000
ST Investments
EBIT TTM
$-6,859,000
Pretax Income TTM
$-6,889,000
Interest Exp TTM
$2,000
Analysts

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 28,855,000 -6,888,000 -7,097,000 24,949,000 12,040,000 -560,000
Dec 2024 21,907,000 -2,737,000 -1,039,000 29,679,000 8,901,000 1,377,000
Dec 2023 21,694,000 -854,000 -922,000 28,059,000 8,163,000 2,079,000
Dec 2022 23,065,000 1,193,000 1,365,000 29,898,000 8,893,000 1,828,000
Dec 2021

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.65

Peers — same industry

TickerNameMarket CapLastDaily %
ACXP Acurx Pharmaceuticals, Inc. $8.34M $1.94
NCNA NuCana plc $8.32M $2.00
IMRN Immuron Ltd $8.25M $1.01
ENVB Enveric Biosciences, Inc. $8.21M $2.23
GNPX Genprex, Inc. $8.17M $0.77

News headlines (Yahoo Finance, 1h cache)

Medicure Inc (MCUJF) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic Acquisitions ...
2026-05-25 21:00 · Yahoo
Medicure Announces AGM Results and Appointment of New Director
2026-05-21 21:00 · Yahoo
Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
2026-05-21 21:00 · Yahoo
Medicure Inc (MCUJF) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Rising Losses
2026-04-28 07:02 · Yahoo
Medicure Reports Financial Results for the Year Ended December 31, 2025 and Schedules April 27, 2026 Conference Call
2026-04-23 22:15 · Yahoo
Medicure Announces Resignation of President and Chief Operating Officer
2026-04-17 23:35 · Yahoo
Medicure: Q3 Earnings Snapshot
2025-11-19 22:21 · Yahoo
Medicure Reports Financial Results for Quarter Ended September 30, 2025
2025-11-19 22:00 · Yahoo
Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025
2025-11-13 22:30 · Yahoo
Medicure Second Quarter 2025 Earnings: CA$0.08 loss per share (vs CA$0.12 loss in 2Q 2024)
2025-08-22 10:41 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.